Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature

Sambhawana Bhandari; Oleg Sostin; Akash Shah; John Chronakos; Douglas Kahn; Jose Mendez; Abhijith Hegde

doi:10.1016/j.rmcr.2023.101891

Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature

Respir Med Case Rep. 2023 Jul 4:45:101891. doi: 10.1016/j.rmcr.2023.101891. eCollection 2023.

Authors

Sambhawana Bhandari¹, Oleg Sostin², Akash Shah³, John Chronakos⁴, Douglas Kahn⁴, Jose Mendez⁴, Abhijith Hegde⁴

Affiliations

¹ Department of Internal Medicine, USA.
² Department of Clinical Research, USA.
³ Primary Care and Informatics, USA.
⁴ Department of Pulmonary and Critical Care Medicine, Nuvance Health, Danbury, CT, USA.

Abstract

Excessive bronchial secretions pose a challenge in mechanically-ventilated patients and may prolong the time to extubation, increasing the risk for pneumonia. Octreotide, a somatostatin analog, has been used to decrease bronchial secretions especially for the symptomatic management of patients with lung cancer. We describe three patients in the form of a case series and discuss effect of octretotide on bronchial secretions and management of bronchorrhea in the intensive care unit. Similar to reports of its utilization in palliative care in patients with lung cancer, we observed a clinically significant decrease in the rate of bronchial secretions.

Keywords: Airway extubation; Mechanical ventilation; Octreotide; Ventilator associated pneumonia.

Publication types

Case Reports